Patients with low tumor ER levels and patients with ER+/PR- disease had a prolonged breast cancer-specific survival after 5 years of TAM therapy as compared to after 2 years and should be encouraged to continue the therapy for 5 years. The gene discussed is ESR1; the disease is breast carcinoma.